Therefore, reducing the secreted IL-8 and IL-6 levels can at least partly explain the benefit of ripasudil in the treatment of HTLV-1-infected hTM cells, further supporting the feasibility of using ripasudil for the relief of secondary glaucoma in HU. The gene discussed is CXCL8; the disease is glaucoma.